What laboratory tests should be ordered to evaluate suspected leukemia in an elderly patient?

Laboratory Testing for Suspected Leukemia in Elderly Patients

For elderly patients with suspected leukemia, begin with a complete blood count (CBC) with differential and peripheral blood smear review, followed immediately by bone marrow aspirate and core biopsy with comprehensive ancillary testing including flow cytometry, conventional cytogenetics (karyotype), FISH, and molecular genetic studies. 1

Initial Blood Tests (Peripheral Blood)

Essential First-Line Tests

• CBC with differential and platelet count - must be performed with pathologist review of peripheral blood smear 1
• Comprehensive metabolic panel - critical for detecting tumor lysis syndrome, particularly important in elderly patients 1
• Lactate dehydrogenase (LDH) - has prognostic relevance 2
• Serum uric acid and phosphate levels - essential for tumor lysis syndrome monitoring 1
• Coagulation panel (PT, PTT, fibrinogen) - mandatory to detect disseminated intravascular coagulation, especially if acute promyelocytic leukemia (APL) is suspected 1

Bone Marrow Evaluation (Strongly Recommended)

Core Diagnostic Procedures

Fresh bone marrow aspirate with core biopsy is required for all patients with suspected acute leukemia, including elderly patients 1. The bone marrow should include:

• Morphologic examination of aspirate smears, touch imprints, cell clots, and core biopsy 1
• Cell count and differential on aspirate material 1

Important caveat: If bone marrow aspirate is unobtainable due to patient instability or dry tap, peripheral blood can be used for diagnosis if sufficient blasts are present (typically ≥5 × 10⁹/L for chronic lymphocytic leukemia or adequate blast count for acute leukemia) 1, 3

Required Ancillary Testing

Immunophenotyping

• Multicolor flow cytometry panel performed on bone marrow aspirate (or peripheral blood if marrow unavailable) - must be comprehensive enough to distinguish AML, APL, B-ALL, T-ALL, and acute leukemia of ambiguous lineage 1
• If flow cytometry material is insufficient, immunohistochemistry on core biopsy can serve as alternative 1

Cytogenetic Analysis (Mandatory)

• Conventional karyotyping - must be performed on bone marrow; this is non-negotiable and cannot be replaced by FISH or molecular testing 1
• FISH studies according to leukemia subtype:
  • For adult AML: Rapid FISH for PML-RARA if APL suspected, plus testing for CBF abnormalities 1
  • For adult ALL: t(9;22)/BCR-ABL1 and KMT2A(MLL) rearrangements 1
  • For chronic lymphocytic leukemia: 4-probe FISH panel (del(17p), del(11q), trisomy 12, del(13q)) 3

Molecular Genetic Testing (Essential for Risk Stratification)

All patients should be tested for the following mutations to guide prognosis and targeted therapy 2:

For AML in elderly patients:

• FLT3-ITD and FLT3-TKD - results should be available rapidly (ideally by day 8) to allow addition of FLT3 inhibitor 2
• NPM1, CEBPA - prognostic markers 1, 2
• IDH1, IDH2 - identifies candidates for IDH inhibitor therapy 1, 2
• TP53 - critical prognostic marker, especially in elderly 1, 2
• RUNX1, ASXL1, TET2, DNMT3A, WT1, KIT - additional prognostic markers 1, 2

For ALL:

• BCR-ABL1 fusion by RT-PCR 1
• IGHV mutational status (particularly for chronic lymphocytic leukemia) - should be determined before first treatment 3

Multiplex gene panels or next-generation sequencing should be obtained for comprehensive prognostic assessment 2, 4

Additional Testing Based on Clinical Presentation

If Extramedullary Disease Suspected

• PET/CT imaging for detection of extramedullary involvement 2
• CSF examination with cell count, cytology, and blast enumeration if CNS symptoms present or for ALL patients receiving intrathecal therapy 1
• Flow cytometry on CSF may be performed 1

Cytochemical Studies (Optional)

• Myeloperoxidase (MPO) and non-specific esterase (NSE) may assist in AML diagnosis and subclassification 1

Critical Pitfalls to Avoid

1. Do not skip conventional karyotyping - FISH and molecular testing do not replace it 1
2. Do not delay FLT3 testing - results needed by day 8 of chemotherapy for treatment decisions 2
3. Ensure adequate sample collection - consult pathology before bone marrow procedure to optimize collection and preservation for all required studies 2
4. Test for TP53 mutations before each line of therapy in elderly patients, as this significantly impacts treatment selection 2, 3
5. If molecular testing unavailable locally, send samples to reference laboratory rather than proceeding without this essential information 2

Sample Priority When Material is Limited

When bone marrow aspirate is limited, prioritize in this order 1:

1. Flow cytometry immunophenotyping
2. Conventional cytogenetics (karyotype)
3. Molecular genetic studies (can use peripheral blood if sufficient blasts present)
4. FISH studies
5. Consider obtaining second core biopsy in tissue culture medium for disaggregation if aspirate completely inadequate 1